Skip to content
value.today

SQZ Biotechnologies Co

🇺🇸 Boston, Massachusetts, USABiotechnologyFounded 2013
Total raised
$167 M
4 rounds on record
Latest round
$66 M
Dec 2019
First round on record
Jun 2015
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of SQZ Biotechnologies Co
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2019$66 MNo. 4$50 to $250 million

SQZ Biotechnologies Co: Raise no. 4, Dec 2019

Investors in this round

27 investors had bought by the notice of Jun 1, 2020: 27 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$66 M of $70 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alexandra W. Balcom · Executive Officer · Treasurer
  • Armon Sharei, Ph.D. · Executive Officer, Director · Founder, CEO & President
  • David W. First · Executive Officer · Chief People Officer
  • Howard W. Bernstein, M.D., Ph.D. · Executive Officer
  • Lawrence W. Knopf · Executive Officer · Secretary and General Counsel
  • Oliver W. Rosen, M.D. · Executive Officer
  • Teri W. Loxam · Executive Officer
  • Amy W. Schulman · Director
  • Eric W. Moessinger · Director
  • Jonathan Fleming · Director
  • Klavs F. Jensen, Ph.D. · Director
  • Marc W. Elia · Director
  • Pushkal W. Garg · Director
  • Zafrira W. Avnur · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Lawrence Knopf, Secretary and General Counsel. Newest notice filed Jun 1, 2020. Read the notice at the SEC.

equitySEC
May 2018$71 MNo. 3$50 to $250 million

SQZ Biotechnologies Co: Raise no. 3, May 2018

Investors in this round

48 investors had bought by the notice of Nov 25, 2019: 48 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$71 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alex A. Balcom · Executive Officer · Treasurer
  • Armon Sharei, Ph.D. · Executive Officer, Director · President, CEO & Secretary
  • Amy W. Schulman · Director
  • Eric W. Moessinger · Director
  • Garry A. Nicholson · Director
  • Jonathan Fleming · Director
  • Klavs F. Jensen, Ph.D. · Director
  • Marc A. Elia · Director
  • Pushkal W. Garg · Director
  • Robert Langer, Sc.D. · Director
  • Zafrira A. Avnur · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Armon Sharei, Ph.D., Chief Executive Officer. Newest notice filed Nov 25, 2019. Read the notice at the SEC.

equitySEC
Sep 2016$24 MNo. 2$10 to $50 million

SQZ Biotechnologies Co: Raise no. 2, Sep 2016

Investors in this round

34 investors had bought by the notice of Dec 1, 2016: 34 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$24 M of $24 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Amy W. Schulman · Executive Officer, Director
  • Armon Sharei, Ph.D. · Executive Officer, Director
  • Howard A. Bernstein · Executive Officer
  • Kris A. Elverum · Executive Officer
  • Eric W. Moessinger · Director
  • Garry A. Nicholson · Director
  • Jonathan Fleming · Director
  • Klavs F. Jensen, Ph.D. · Director
  • Mark W. Murcko, Ph.D. · Director
  • Robert S. Langer, Sc.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Armon Sharei, Ph.D, Chief Executive Officer. Newest notice filed Dec 1, 2016 (1 amendment). Read the notice at the SEC.

equitySEC
Jun 2015$5 MNo. 1$2 to $10 million

SQZ Biotechnologies Co: Raise no. 1, Jun 2015

Investors in this round

24 investors had bought by the notice of Jul 28, 2015: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Armon Sharei, Ph.D. · Executive Officer, Director
  • Amy W. Schulman · Director
  • Jonathan Fleming · Director
  • Klavs F. Jensen, Ph.D. · Director
  • Robert Langer, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Armon Sharei, Ph.D., Chief Executive Officer. Newest notice filed Jul 28, 2015 (1 amendment). Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • SQZ Biotechnologies Co chose not to state its revenue in its newest notice of a funding round (Jun 2020).

    SEC Form D · Jun 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2020

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of SQZ Biotechnologies Co is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by SQZ Biotechnologies Co
NameRoleNamed in
Alexandra W. BalcomTreasurerJun 2020
Armon Sharei, Ph.D.Founder, CEO & PresidentJun 2020
David W. FirstChief People OfficerJun 2020
Howard W. Bernstein, M.D., Ph.D.Executive officerJun 2020
Lawrence W. KnopfSecretary and General CounselJun 2020
Oliver W. Rosen, M.D.Executive officerJun 2020
Teri W. LoxamExecutive officerJun 2020
Alex A. BalcomTreasurerNov 2019
Amy W. SchulmanExecutive officerDec 2016
Howard A. BernsteinExecutive officerDec 2016
Kris A. ElverumExecutive officerDec 2016
Howard W. BernsteinExecutive officerOct 2016
Kris W. ElverumExecutive officerOct 2016
Amy W. SchulmanDirectorJun 2020
Armon Sharei, Ph.D.Founder, CEO & PresidentJun 2020
Eric W. MoessingerDirectorJun 2020
Jonathan FlemingDirectorJun 2020
Klavs F. Jensen, Ph.D.DirectorJun 2020
Marc W. EliaDirectorJun 2020
Pushkal W. GargDirectorJun 2020
Zafrira W. AvnurDirectorJun 2020
Garry A. NicholsonDirectorNov 2019
Marc A. EliaDirectorNov 2019
Robert Langer, Sc.D.DirectorNov 2019
Zafrira A. AvnurDirectorNov 2019
Mark W. Murcko, Ph.D.DirectorDec 2016
Robert S. Langer, Sc.D.DirectorDec 2016
Garry W. NicholsonDirectorOct 2016
Robert Langer, Ph.D.DirectorJul 2015